AMG 510 (sotorasib) was the first drug candidate which demonstrated success in clinical trials for KRAS-mutant cancers, especially NSCLC patients with KRAS-G12C mutation (32.2% achieved objective response and 88.1% achieved disease control) [95,96,97]. This evidence concerns the gene KRAS and cancer.